Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) have been assigned an average recommendation of “Moderate Buy” from the six research firms that are presently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and four have given a buy recommendation to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $37.3333.

Several research firms have issued reports on NBTX. UBS Group boosted their price objective on shares of Nanobiotix from $3.50 to $30.00 and gave the stock a “neutral” rating in a research note on Friday, May 1st. Guggenheim boosted their target price on shares of Nanobiotix from $26.00 to $36.00 and gave the stock a “buy” rating in a research report on Thursday, April 2nd. Leerink Partners upped their target price on shares of Nanobiotix from $37.00 to $46.00 and gave the company an “outperform” rating in a research note on Thursday, June 4th. TD Cowen reaffirmed a “buy” rating on shares of Nanobiotix in a report on Thursday, March 12th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Nanobiotix in a research note on Tuesday, April 21st.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the business. Millennium Management LLC acquired a new stake in Nanobiotix during the 4th quarter valued at approximately $390,000. Marshall Wace LLP acquired a new position in shares of Nanobiotix in the 4th quarter valued at approximately $220,000. Finally, Royal Bank of Canada raised its position in shares of Nanobiotix by 2,000.0% in the 4th quarter. Royal Bank of Canada now owns 2,625 shares of the company’s stock valued at $61,000 after purchasing an additional 2,500 shares in the last quarter. Institutional investors and hedge funds own 38.81% of the company’s stock.

Nanobiotix Price Performance

NBTX opened at $38.80 on Wednesday. Nanobiotix has a 1 year low of $4.93 and a 1 year high of $57.14. The firm has a 50 day moving average price of $39.34 and a 200 day moving average price of $31.32.

Nanobiotix Company Profile

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.